Related Experiment Video
Updated: Nov 6, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
[INFLUENCE OF COMBINED ERADICATION AND PROKINETIC THERAPY ON CLINICAL MANIFESTATIONS, PSYCHOLOGICAL STATUS AND
G Solovyova1, K Kvacheniuk2, T Alianova3
11Bogomolets National Medical University, Kyiv; 2Gastro center of the Clinic "Oberig", Kyiv; Ukraine.
Abstract:
Functional dyspepsia - postprandial distress-syndrome (FD-PDS) is one of the most common reasons for seeking medical attention of general practitioners, internists and gastroenterologists worldwide. Standard approaches to the treatment of patients with postprandial distress syndrome are only effective in small amount of cases. Aim of the study - comparative assessment of the effectiveness of combined eradication and prokinetic therapy and eradication therapy only in the treatment of FD-PDS by studying their effect on the clinical manifestations of the disease, patients' psychological status and quality of life. This was a randomized prospective study among patients with FD-PDS in the presence of Helicobater pylori invasion. Participants from group 1 - 65 patients - received eradication therapy and prokinetic itoprid hydrochloride 50 mg three times a day; participants in group 2 - 61 patients - received only eradication therapy for 14 days. Helicobacter pylori was evaluated using a rapid one-step immunochromatographic test to detect stool antigen, or using PCR for Helicobacter pylori DNA, or using a histological method. To assess the severity of dyspeptic and concomitant gastroenterological symptoms, a 7-point Likert scale was used; to assess the severity of anxiety and depression in dynamics - Hospital Anxiety and Depression Scale (HADS); to assess the quality of life indicators - the SF-36 questionnaire. The duration of the study was 30 days. Combined eradication and prokinetic therapy, in comparison with eradication therapy only, is more effective in the treatment of FD-PDS. The additional use of itopride hydrochloride contributes to a more effective decrease in the severity and a longer elimination of symptoms of the disease (p˂0.05), helps to reduce the level of depression (p=0.002) and improve the quality of life indicators on the scales of physical functioning (p=0.032), role-physical functioning (p=0.039), bodily pain (p=0.0001), general health (p = 0.041), vitality (p=0.0001), social functioning (p=0.048).
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

